Peer Review History
| Original SubmissionFebruary 3, 2021 |
|---|
|
PONE-D-21-03821 Arabic validation and cross-cultural adaptation of the 5C scale for assessment of COVID-19 vaccines psychological antecedents PLOS ONE Dear Dr. Elbarazi, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The reviewers were unanimous on the need to further improve the methodological clarity of the paper and highlighted multiple weaknesses in the introduction and discussion sections. I agreed with the concerns of the three reviewers and would encourage you to submit a revision addressing these concerns as much as possible. Please submit your revised manuscript by May 22 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Adewale L. Oyeyemi, Ph.D Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. 3. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information. 4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Introduction * Authors mention in the introduction the use of different instruments that measure vaccine acceptance. Why did they use this particular instrument 5C? How it compares with others? * Need some more information about the history of the development of this instrument, where has it been previously used, among which populations and at what behavioral settings, were there any psychometric properties established, has the instrument been applied successfully in other settings? Are there any limitations regarding using this instrument? * It is stated that certain countries like Kuwait and Jordan have lower acceptance rate of the vaccine. Why is that? How do the authors explain this hesitancy within the population of these two Arab countries? * No need to include the word “respectively” since the percentages are shown next to each country. * Why is this study significant from a measurement perspective but most importantly from a public health perspective? * What is the research question that this study is trying to answer? Methods: * The items of each scale need to be included in a narrative format and not in bullet format. There should be an introductory sentence like: The following are the items of the scale. * There is a lot of quoting, avoid quotations as much as possible and simply paraphrase. * In the methods sections, the other demographic variables are not included. These should be also included in the description of the variables besides the cognitive variables of the 5C * It is not clear why the authors did not calculate the score of a variable. Can they give an example? Also, why didn’t the authors create a dependent variable like the intention to get the vaccine once available ao that they can test the predictability of these variables since they were planning to collect the data anyways? * Regarding the cognitive interviews, can the authors give examples of the questions they asked? How much time each cognitive interview took place? How did they analyze the results? What is the demographic picture of the people participating in the cognitive interviews? Were the interviews in a sense the pretesting of the survey? This is not clear. * I am not sure if I understand whether the authors claim to have used a random sample or not. They state that the countries selected were random. It is hard to believe that because to do such a multi-country study one needs to have established collaborative relationships with researchers from that country. In addition, the survey was distributed via social media, whatsapp etc. I guess, one person was forwarding the email to another person, correct? In other words, this was convenience sampling and not random. A random sample would have been if a huge list of potential participants was given to the researchers and they chose randomly 600 of those and sent them the survey via email etc. How were the participants recruited? It is not clear. * Under data management and psychometric analysis the authors write that “ qualitative data were presented with percent and frequency”. Qualitative data refers to text and comments. Did the authors mean something else? * Was the survey written in classical or formative Arabic language? Were there any difficulties in understanding some of the words even in classical Arabic given the different dialects? Results: * The results seem well written however, one can see from the demographics that the study sample is skewed towards the higher educated populations since almost 80% of the study population were at least University graduates. Another observation is that authors do not mention the ethnic group of the participants, just the country. Were all participants Arabs? This was not clear. * Another observation is that more than one third of the participants had a relative who died from COVID. This could have influenced the motivation to accept the vaccine. I would suggest that one of the exclusion criteria in the recruitment process was having a relative who died from Covid because this subpopulation might have different motivations toward getting the vaccine compared to the general public because of witnessing a loved one dying from COVID. Were any exclusion criteria established? Discussion * The authors claim that the results of the study are representative of the Arab region. This is true up to an extent, countries like Lebanon, Jordan and Syria, the Levant region are not included. Are those represented as well? * The discussion was very shallow and it is focused mostly on the psychological interpretations of the results. The authors used vague terms like “ the individual” or the “people”. Well these people are Arab people. I suggest that the author interpret the result through the lenses of Arab culture and Islamic religion. For instance it is well known, that Arab societies are collectivist societies, how does that relate to the results? What about the trust in God or fate, that if someone gets sick it was meant to happen? Or that disease is perhaps punishment from God? How can public health professionals who plan interventions to promote vaccine acceptance in these countries can use the results of this study? * How do the authors interpret the results based on the fact that almost a third of the sample had someone who had died from COVID? Do they think that might have influenced the way the participants answered the questions or not? * What are the study limitations? Reviewer #2: In general, it is a very interesting topic specially that validations scales in Arabic are very needed studies. Researches have done good job in the statistical analysis of the study and explained their methodology very well. Few suggestions can be provided to make the paper sound even better: Introduction: 1. The flow of the introduction can be improved paragraph1 is about the outbreak of COVID-19. Paragraph2 facing COVID-19 globally. Paragraphs 3,4 and 5 can be combined about the COVID-19 vaccine. Other paragraphs can be used to introduce: acceptance of the vaccine globally, if there are different tools used to understand vaccine psychological impact, if there any theoretical and conceptual framework used to develop the current tool, and finally stating the aim of the study. Method: 2. The method section is too long! Is there a way to shorten it? Keep important information in the method section and extra information in the supporting document if this is possible. 3. For study tool for example, keep the sub-scales and their definitions. Categories of the subscales can be moved in the supporting document. 4. Although the mode of the survey was mentioned, it is not clear to me how the study targeted the population of the four countries Egypt, Libya, UAE and KSA? The availability of the survey online means that the survey was open to anyone from any country? What measures or strategies researchers did to ensure targeting the specified countries mentioned? This need to be explained to remove ambiguity. 5. Score interpretation: can you further clarified, and refined in a simpler way for the readers to understand. 6. Translation and adaptation: how many total researchers/co-authors/ translators worked for this section? This section can be refined by stating the total number of individuals who worked on this section and then each stage of the translation should state the number of individuals who worked at that stage. 7. Translation and adaptation: are the same translators who translated the tool into Arabic assessed the translation or separate individuals? Just to avoid bias 8. Cognitive interviews: you mean piloting right? What about adding the word “pilot” since people are more familiar with the word pilot compared to cognitive interview? Or is it because it is a psychological study the term cognitive interview is preferred compared to the word piloting? 9. Do you think this paragraph: Based on the sample size recommendations of having 10 participants respond to each item for validating a questionnaire (ratio 10:1), we needed 150 participants [25]. 8 Moreover, a priori sample size calculation for Structural Equation Modelling (SEM) technique to perform confirmatory factor analysis (CFA) showed that a minimum sample of 200 is required to run CFA [26]. For that, the minimum required sample size for our analysis was 350 participants. Adult (18 years and above) Arabic speaking population is included in the study, should be labeled as a sample size calculation or study sample size? 10. Do you think this paragraph: The final Arabic copy of 5C scale was uploaded on Qualtrics and disseminated online via different social media platforms (Facebook, WhatsApp, emails, and Twitter) to 673 participants? The sample was recruited from four randomly selected Arabic countries (Egypt, Saudi Arabia. Libya, and United Arab of Emirates (UAE)). A total of 511 responded to the questionnaire, 89 participants chose not to complete the questionnaire. The response rate was 62.70% (422/673). Of the 422 who completed the questionnaire, we excluded 72 responses from the final analysis due to incomplete or inconsistent data. The final sample size included in our analysis was 350 participants, could be labeled as data source? 11. What about adding: time frame of the study? When did the data collection start and ended? For how long the survey was open to participants? 12. Do you think converting the paragraph above to “figure as a flow chart for participant recruitment”, will make it easier for the reader? 13. What about clarifying the design of the study and stating that it is a quantitative and a cross sectional study? Discussion: 14. Discussion should focus on interpreting the main results of the study no repeating the results 15. Comparing the results of the Arab words to studies conducted elsewhere (missing?) 16. Strengths and limitation of the study (missing?) Conclusion: 17. Why there is no separate conclusion to this study? 18. Conclusion should summarize main findings, any policy implications of the study, any recommendations, any future research to answer or understand questions raised by this study Reviewer #3: This manuscript is well written. However, there are some comments that need clarifications. Introduction: Page 4 second paragraph: Authors need to differentiate between the acceptability and the availability of the vaccine in these listed countries. As these countries varies in their economic status and the availability/ affordability of the vaccine. Methodology: the study design should be clearly mentioned, and the authors should make is clear that they used a mixed approach (both qualitative and quantitative). Also, the reasons behind using the mixed approach (quantitative and the qualitative). Its not clear how the participants were recruited from four selected Arabic countries? how did they select the four countries randomly? (Egypt, Saudi Arabia. Libya, and United Arab of Emirates (UAE). The authors mentioned that the four Arab countries were randomly selected. it’s not clear how they selected these countries in a random basis? and why four and not more or less? By reading the manuscript, I thought that the sampling methodology is non-proportional convenient sampling. Those included in the study are participants who are available and volunteered to participate. Page 8 at the end of paragraph 1 " we excluded 72 responses from the final analysis due to incomplete or inconsistent data". Are these questionnaires distributed over selected countries? what is the percentage from each country? End of page 8, beginning of page 9, its not clear how the researchers measure the construct validity and how they randomly divide the sample into 2 groups one with 150 and the other with 200? The translated Arabic version of the questionnaire should be provided with the manuscript. Results: Because there is high discrepancy between the lowest and the highest age that affected the mean, its better to categorize the age and then run the analysis. Also, about one third of the participants are from Egypt whose Arabic accent and words meaning to some extent is different than other Arab countries. Also, none of the following countries are included in the sample (Jordan, Lebanon, Syria, and Palestine) who have seminaries in Arabic while they are different than other Arab countries, this might create bias in sample selection and the results. Discussion Page 11: I disagree with the authors statement “Therefore, chosen countries in this study are good representative of the Arab region". They missed to include one representative country from: (Jordan, Lebanon, Syria, and Palestine). Authors should mention that. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: Yes: Haleama Al Sabbah [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Arabic validation and cross-cultural adaptation of the 5C scale for assessment of COVID-19 vaccines psychological antecedents PONE-D-21-03821R1 Dear Dr. Elbarazi, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Adewale L. Oyeyemi, Ph.D Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #3: I would like to congratulate the authors of this manuscript who did a great job in revising the manuscript and endorsed all my comments. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #3: Yes: Haleama Al Sabbah |
| Formally Accepted |
|
PONE-D-21-03821R1 Arabic validation and cross-cultural adaptation of the 5C scale for assessment of COVID-19 vaccines psychological antecedents Dear Dr. Elbarazi: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Adewale L. Oyeyemi Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .